Background Anti-CCP antibodies are known to be related to more erosive disease in rheumatoid arthritis (RA). In recent years these antibodies are found to be increased in chronic obstructive pulmonary disease, liver disease, autoinflammatory diseases and cigarette smoking as well.
Objectives In this study we searched whether additional factors such as lung, thyroid, liver problems and smoking had any contribution to anti-CCP levels in RA patients.
Methods One hundred and thirteen RA patients who followed up in our rheumatology outpatient clinics participated in the study. In addition to demographic features, pulmonary function test results, anti thyroglobulin (anti TG ab) and anti thyro peroxidase (anti TPO ab) antibodies, hepatitis markers, erythrocyte sedimentation rate (ESR), C- reactive protein, rheumatiod factor (RF) and anti- CCP levels were evaluated.
Results Mean values of the parameters were as follows: age of the patients: 54.76±11.56; disease duration: 10.9±7.2 years, forced expiratory volume 1: 79.5±21.33, forced vital capacity: 81.85±16.73. Levels of anti TG ab was high in 9.7% and that of anti TPO ab was high in 18.6% of the patients. 10% of the patients were Hepatitis B carrier. 72.6% of the patients were smoking cigarette. We divide the patients into 2 groups according to anti- CCP levels (higher or lower then 60 units). We found statistical significant difference in anti TG ab levels (p: 0.04), RF levels (p: 0.00) and ESR (p: 0.001).
Conclusions It is well known that RF and ESR levels are related with anti- CCP levels, in addition to these we found anti TG antibodies could also increase anti -CCP levels. It is necessary to make studies with larger samples for more precise decisions.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.